News
# World’s First AI-Discovered and Designed Drug Enters Phase III Trials as Shanghai Builds a Biomanufacturing Hub
On September 10, 2026, a patient at Peking Union Medical College Hospital in Beijing received a dose of an unusual drug. The first participant in a Phase III clinical trial took rentosertib, a small-m…
Oct 23, 2026
Read More
**Shanghai’s Industries of the Future | From Waste Plastic to Crystal-Clear Bottles: How a Shanghai Company Is Rethinking Protein R&D with AI**
A row of bottles sits on display in Matwings’ showroom. Some of the clearest and most brilliant were made from discarded water bottles and old bedsheets.
Behind them is a plastic-degrading enzy…
Oct 22, 2026
Read More
Matwings: Putting a “Biological Engine” in the Chemical Industry
Matwings has built a closed-loop capability that combines computational design with experimental validation and industrial deployment. Its work in AI-driven protein design goes beyond algorithms and…
Oct 21, 2026
Read More
Matwings Demonstrates Closed-Loop Protein AI Through Four AI–Wet Lab Cycles and 222 Protein Variants
The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints
SHANGHAI, August 20]、, 2026 -- Shanghai Matwings T…
Aug 20, 2026
Read More
Matwings Technology's Gen Z Scientist-Led VenusREM Emerges as Authoritative Industry Reference for Protein Mutation Prediction
A preprint titled PG-LLM: Benchmarking General-Purpose Language Models for Protein Variant Ranking, recently released by a research collaboration between Harvard University and Capable, p…
Aug 12, 2026
Read More
AI-Powered Drug Discovery Delivers Not "Lottery-Style Disruption," But "A Steady Stream of Small Wins"
The true bottleneck in AI-driven pharmaceutical R&D is not the model itself.
On August 6, during BPD 2026, the special forum "AI-Empowered Innovative Drug R&D and Application Pra…
Aug 10, 2026
Read More
-&e5&b0&81&e9&9d&a2.jpg)
